Search tips
Search criteria 


Logo of aacPermissionsJournals.ASM.orgJournalAAC ArticleJournal InfoAuthorsReviewers
Antimicrob Agents Chemother. 1995 January; 39(1): 125–131.
PMCID: PMC162497

Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS.


Simian immunodeficiency virus (SIV) infection of newborn rhesus macaques is a practical animal model of pediatric AIDS. Intravenous inoculation of rhesus newborns with uncloned SIVmac resulted in a high virus load, no antiviral immune responses, severe immunodeficiency, and a high mortality rate within 3 months. In contrast, immediate oral zidovudine (AZT) treatment of SIV-inoculated rhesus newborns either prevented infection or resulted in reduced virus load, enhanced antiviral immune responses, a low frequency of AZT-resistant virus isolates, and delayed disease progression with negligible toxicity. These results suggest that early chronic AZT treatment of human immunodeficiency virus-exposed newborns may have benefits that outweigh its potential side effects.

Full Text

The Full Text of this article is available as a PDF (238K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Blanche S, Rouzioux C, Moscato ML, Veber F, Mayaux MJ, Jacomet C, Tricoire J, Deville A, Vial M, Firtion G, et al. A prospective study of infants born to women seropositive for human immunodeficiency virus type 1. HIV Infection in Newborns French Collaborative Study Group. N Engl J Med. 1989 Jun 22;320(25):1643–1648. [PubMed]
  • Blanche S, Duliege AM, Navarette MS, Tardieu M, Debré M, Rouzioux C, Seldrup J, Kouzan S, Griscelli C. Low-dose zidovudine in children with an human immunodeficiency virus type 1 infection acquired in the perinatal period. Pediatrics. 1991 Aug;88(2):364–370. [PubMed]
  • Bohm RP, Jr, Martin LN, Davison-Fairburn B, Baskin GB, Murphey-Corb M. Neonatal disease induced by SIV infection of the rhesus monkey (Macaca mulatta). AIDS Res Hum Retroviruses. 1993 Nov;9(11):1131–1137. [PubMed]
  • Borkowsky W, Krasinski K, Paul D, Holzman R, Moore T, Bebenroth D, Lawrence R, Chandwani S. Human immunodeficiency virus type 1 antigenemia in children. J Pediatr. 1989 Jun;114(6):940–945. [PubMed]
  • Boucher FD, Modlin JF, Weller S, Ruff A, Mirochnick M, Pelton S, Wilfert C, McKinney R, Jr, Crain MJ, Elkins MM, et al. Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. J Pediatr. 1993 Jan;122(1):137–144. [PubMed]
  • Buseyne F, Blanche S, Schmitt D, Griscelli C, Rivière Y. Detection of HIV-specific cell-mediated cytotoxicity in the peripheral blood from infected children. J Immunol. 1993 Apr 15;150(8 Pt 1):3569–3581. [PubMed]
  • Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, VanDyke R, Bey M, Shearer W, Jacobson RL, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994 Nov 3;331(18):1173–1180. [PubMed]
  • Desrosiers RC. The simian immunodeficiency viruses. Annu Rev Immunol. 1990;8:557–578. [PubMed]
  • Epstein LG, Boucher CA, Morrison SH, Connor EM, Oleske JM, Lange JM, van der Noordaa J, Bakker M, Dekker J, Scherpbier H, et al. Persistent human immunodeficiency virus type 1 antigenemia in children correlates with disease progression. Pediatrics. 1988 Dec;82(6):919–924. [PubMed]
  • Gabiano C, Tovo PA, de Martino M, Galli L, Giaquinto C, Loy A, Schoeller MC, Giovannini M, Ferranti G, Rancilio L, et al. Mother-to-child transmission of human immunodeficiency virus type 1: risk of infection and correlates of transmission. Pediatrics. 1992 Sep;90(3):369–374. [PubMed]
  • Husson RN, Shirasaka T, Butler KM, Pizzo PA, Mitsuya H. High-level resistance to zidovudine but not to zalcitabine or didanosine in human immunodeficiency virus from children receiving antiretroviral therapy. J Pediatr. 1993 Jul;123(1):9–16. [PubMed]
  • Japour AJ, Mayers DL, Johnson VA, Kuritzkes DR, Beckett LA, Arduino JM, Lane J, Black RJ, Reichelderfer PS, D'Aquila RT, et al. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group. Antimicrob Agents Chemother. 1993 May;37(5):1095–1101. [PMC free article] [PubMed]
  • Kellam P, Boucher CA, Larder BA. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1934–1938. [PubMed]
  • Kestler H, Kodama T, Ringler D, Marthas M, Pedersen N, Lackner A, Regier D, Sehgal P, Daniel M, King N, et al. Induction of AIDS in rhesus monkeys by molecularly cloned simian immunodeficiency virus. Science. 1990 Jun 1;248(4959):1109–1112. [PubMed]
  • Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science. 1989 Mar 31;243(4899):1731–1734. [PubMed]
  • Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science. 1989 Dec 1;246(4934):1155–1158. [PubMed]
  • Lohman BL, Higgins J, Marthas ML, Marx PA, Pedersen NC. Development of simian immunodeficiency virus isolation, titration, and neutralization assays which use whole blood from rhesus monkeys and an antigen capture enzyme-linked immunosorbent assay. J Clin Microbiol. 1991 Oct;29(10):2187–2192. [PMC free article] [PubMed]
  • Lohman BL, McChesney MB, Miller CJ, McGowan E, Joye SM, Van Rompay KK, Reay E, Antipa L, Pedersen NC, Marthas ML. A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge. J Virol. 1994 Nov;68(11):7021–7029. [PMC free article] [PubMed]
  • Lopez-Anaya A, Unadkat JD, Schumann LA, Smith AL. Pharmacokinetics of zidovudine (azidothymidine). II. Development of metabolic and renal clearance pathways in the neonate. J Acquir Immune Defic Syndr. 1990;3(11):1052–1058. [PubMed]
  • Luzuriaga K, Koup RA, Pikora CA, Brettler DB, Sullivan JL. Deficient human immunodeficiency virus type 1-specific cytotoxic T cell responses in vertically infected children. J Pediatr. 1991 Aug;119(2):230–236. [PubMed]
  • Luzuriaga K, McQuilken P, Alimenti A, Somasundaran M, Hesselton R, Sullivan JL. Early viremia and immune responses in vertical human immunodeficiency virus type 1 infection. J Infect Dis. 1993 May;167(5):1008–1013. [PubMed]
  • McKinney RE, Jr, Maha MA, Connor EM, Feinberg J, Scott GB, Wulfsohn M, McIntosh K, Borkowsky W, Modlin JF, Weintrub P, et al. A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group. N Engl J Med. 1991 Apr 11;324(15):1018–1025. [PubMed]
  • Ochs HD, Morton WR, Tsai CC, Thouless ME, Zhu Q, Kuller LD, Wu YP, Benveniste RE. Maternal-fetal transmission of SIV in macaques: disseminated adenovirus infection in an offspring with congenital SIV infection. J Med Primatol. 1991 Jun;20(4):193–200. [PubMed]
  • O'Sullivan MJ, Boyer PJ, Scott GB, Parks WP, Weller S, Blum MR, Balsley J, Bryson YJ. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Zidovudine Collaborative Working Group. Am J Obstet Gynecol. 1993 May;168(5):1510–1516. [PubMed]
  • Para MF. Use of zidovudine following occupational exposure to human immunodeficiency virus. Clin Infect Dis. 1992 Nov;15(5):884–885. [PubMed]
  • Pizzo PA, Eddy J, Falloon J, Balis FM, Murphy RF, Moss H, Wolters P, Brouwers P, Jarosinski P, Rubin M, et al. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med. 1988 Oct 6;319(14):889–896. [PubMed]
  • Pollack H, Zhan MX, Ilmet-Moore T, Ajuang-Simbiri K, Krasinski K, Borkowsky W. Ontogeny of anti-human immunodeficiency virus (HIV) antibody production in HIV-1-infected infants. Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2340–2344. [PubMed]
  • Richman DD. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob Agents Chemother. 1993 Jun;37(6):1207–1213. [PMC free article] [PubMed]
  • Richman DD, Fischl MA, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Hirsch MS, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):192–197. [PubMed]
  • Richman DD, Grimes JM, Lagakos SW. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr. 1990;3(8):743–746. [PubMed]
  • Saag MS, Crain MJ, Decker WD, Campbell-Hill S, Robinson S, Brown WE, Leuther M, Whitley RJ, Hahn BH, Shaw GM. High-level viremia in adults and children infected with human immunodeficiency virus: relation to disease stage and CD4+ lymphocyte levels. J Infect Dis. 1991 Jul;164(1):72–80. [PubMed]
  • Scott GB, Hutto C, Makuch RW, Mastrucci MT, O'Connor T, Mitchell CD, Trapido EJ, Parks WP. Survival in children with perinatally acquired human immunodeficiency virus type 1 infection. N Engl J Med. 1989 Dec 28;321(26):1791–1796. [PubMed]
  • Sutjipto S, Pedersen NC, Miller CJ, Gardner MB, Hanson CV, Gettie A, Jennings M, Higgins J, Marx PA. Inactivated simian immunodeficiency virus vaccine failed to protect rhesus macaques from intravenous or genital mucosal infection but delayed disease in intravenously exposed animals. J Virol. 1990 May;64(5):2290–2297. [PMC free article] [PubMed]
  • Tindall B, Carr A, Goldstein D, Penny R, Cooper DA. Administration of zidovudine during primary HIV-1 infection may be associated with a less vigorous immune response. AIDS. 1993 Jan;7(1):127–128. [PubMed]
  • Van Rompay KK, Marthas ML, Ramos RA, Mandell CP, McGowan EK, Joye SM, Pedersen NC. Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: oral 3'-azido-3'-deoxythymidine prevents SIV infection. Antimicrob Agents Chemother. 1992 Nov;36(11):2381–2386. [PMC free article] [PubMed]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)